製薬業界における AI: リスク、リターン、そして今後の展望

人工知能(AI)の利用は今やあらゆる業界に浸透しており、製薬業界も例外ではありません。既存のデータに基づいて予測を行う機械学習(ML)モデルや、トレーニングデータに基づいて新しいデータを生成する生成AI(GenAI)モデルなど、AIは研究から承認、マーケティングに至るまで、薬品開発プロセスの各ステップを効率化し、加速するために活用されています。

当社独自のホワイトペーパーで、製薬業界におけるAIについて詳細をご確認いただけます。

''
Citeline may contact you about relevant products, services and content. To opt-out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.

Thank you.




Your download should open in a new window. You can also manually download by clicking the button below.



Related resources

AI assistant in biotechnology science experiment
JUL 15, 2024
Article
Clinical

The Promise and Peril of AI in Clinical Trials

Many smaller organizations have not yet implemented a specialized clinical trial disclosure system. Robust transparency, and perhaps even just compliance with multiple regulators, requires commitment from the C-suite for companies of all sizes.

Synthetic Data Generation
SEP 05, 2024
Article
Clinical

The Real Value of Synthetic Data in Clinical Research: 3 Use Cases

Synthetic data, a form of generative AI, focuses on the creation of new content. See three use cases for using synthetic data in clinical research.

CNS Summit-resource-card-thumbnail
NOV 09, 2023
Video
Clinical

The Cutting Edge of Pharma: AI and RWD

Thought leaders from Norstella and Citeline shared their expert insights on artificial intelligence and real-world data at the CNS Summit.